EG 102
Alternative Names: EG-102Latest Information Update: 23 Jun 2022
At a glance
- Originator Evergreen Therapeutics
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Focal segmental glomerulosclerosis
Most Recent Events
- 11 Apr 2022 Shenzhen Eglin Pharmaceutical has patent protection for EG 102 (Evergreen Therapeutics pipeline, April 2022)
- 11 Apr 2022 Preclinical trials in Focal segmental glomerulosclerosis in China (unspecified route) (Evergreen Therapeutics pipeline, April 2022)
- 11 Apr 2022 EG 102 receives Orphan Drug status for Focal segmental glomerulosclerosis in China (Evergreen Therapeutics pipeline, April 2022)